The MYC oncogene is a global regulator of the immune response

被引:175
作者
Casey, Stephanie C. [1 ]
Baylot, Virginie [1 ]
Felsher, Dean W. [1 ,2 ]
机构
[1] Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
SUSTAINED TUMOR-REGRESSION; I GENE-EXPRESSION; HLA CLASS-I; NF-KAPPA-B; C-MYC; PD-L1; EXPRESSION; CELLULAR SENESCENCE; THERAPEUTIC TARGET; BROMODOMAIN INHIBITOR; RECEPTOR EXPRESSION;
D O I
10.1182/blood-2017-11-742577
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The MYC proto-oncogene is a gene product that coordinates the transcriptional regulation of a multitude of genes that are essential to cellular programs required for normal as well as neoplastic cellular growth and proliferation, including cell cycle, self-renewal, survival, cell growth, metabolism, protein and ribosomal biogenesis, and differentiation. Here, we propose that MYC regulates these programs in a manner that is coordinated with a global influence on the host immune response. MYChad been presumed to contribute to tumorigenesis through tumor cell-intrinsic influences. More recently, MYC expression in tumor cells has been shown to regulate the tumor microenvironment through effects on both innate and adaptive immune effector cells and immune regulatory cytokines. Then, MYC was shown to regulate the expression of the immune checkpoint gene products CD47 and programmed death-ligand 1. Similarly, other oncogenes, which are known to modulate MYC, have been shown to regulate immune checkpoints. Hence, MYC may generally prevent highly proliferative cells from eliciting an immune response. MYC-driven neoplastic cells have coopted this mechanism to bypass immune detection. Thus, MYC inactivation can restore the immune response against a tumor. MYC-induced tumors may be particularly sensitive to immuno-oncology therapeutic interventions.
引用
收藏
页码:2007 / 2015
页数:9
相关论文
共 133 条
  • [1] Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
    Abruzzese, Maria Pia
    Bilotta, Maria Teresa
    Fionda, Cinzia
    Zingoni, Alessandra
    Soriani, Alessandra
    Vulpis, Elisabetta
    Borrelli, Cristiana
    Zitti, Beatrice
    Petrucci, Maria Teresa
    Ricciardi, Maria Rosaria
    Molfetta, Rosa
    Paolini, Rossella
    Santoni, Angela
    Cippitelli, Marco
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy H.
    Christensen, Camilla L.
    Mikse, Oliver R.
    Cherniack, Andrew D.
    Beauchamp, Ellen M.
    Pugh, Trevor J.
    Wilkerson, Matthew D.
    Fecci, Peter E.
    Butaney, Mohit
    Reibel, Jacob B.
    Soucheray, Margaret
    Cohoon, Travis J.
    Janne, Pasi A.
    Meyerson, Matthew
    Hayes, D. Neil
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Hammerman, Peter S.
    Dranoff, Glenn
    Wong, Kwok-Kin
    [J]. CANCER DISCOVERY, 2013, 3 (12) : 1355 - 1363
  • [3] The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
    Asano, T
    Yao, YX
    Zhu, JJ
    Li, DH
    Abbruzzese, JL
    Reddy, SAG
    [J]. ONCOGENE, 2004, 23 (53) : 8571 - 8580
  • [4] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
    Atefi, Mohammad
    Avramis, Earl
    Lassen, Amanda
    Wong, Deborah J. L.
    Robert, Lidia
    Foulad, David
    Cerniglia, Michael
    Titz, Bjoern
    Chodon, Thinle
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Ribas, Antoni
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3446 - 3457
  • [5] PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
    Atsaves, V.
    Tsesmetzis, N.
    Chioureas, D.
    Kis, L.
    Leventaki, V.
    Drakos, E.
    Panaretakis, T.
    Grander, D.
    Medeiros, L. J.
    Young, K. H.
    Rassidakis, G. Z.
    [J]. LEUKEMIA, 2017, 31 (07) : 1633 - 1637
  • [6] c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
    Baudino, TA
    McKay, C
    Pendeville-Samain, H
    Nilsson, JA
    Maclean, KH
    White, EL
    Davis, AC
    Ihle, JN
    Cleveland, JL
    [J]. GENES & DEVELOPMENT, 2002, 16 (19) : 2530 - 2543
  • [7] N-MYC AMPLIFICATION CAUSES DOWN-MODULATION OF MHC CLASS-I ANTIGEN EXPRESSION IN NEUROBLASTOMA
    BERNARDS, R
    DESSAIN, SK
    WEINBERG, RA
    [J]. CELL, 1986, 47 (05) : 667 - 674
  • [8] Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins
    Bouchard, C
    Marquardt, J
    Brás, A
    Medema, RH
    Eilers, M
    [J]. EMBO JOURNAL, 2004, 23 (14) : 2830 - 2840
  • [9] BRAUN J, 1992, ANN NY ACAD SCI, V651, P467
  • [10] Caimi P, 2017, HEMATOL ONCOL, V35, P263